Eli Lilly’s blowout quarter should quiet investor concerns about the stock

Earnings

Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. 
George Frey | Bloomberg | Getty Images

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock.

Articles You May Like

Warner Bros. Discovery adds 7.2 million Max subscribers, the streamer’s largest single-quarter jump
Philadelphia Phillies capital raise values the team at around $3 billion
Singapore Airlines shares fall 6% as profit nearly halves amid intensifying competition
Big retirement rule changes are coming in 2025 — here’s how you can save more money
Family offices becoming ‘economic powerhouse’ in private company deals

Leave a Reply

Your email address will not be published. Required fields are marked *